[1] Zaridze DG. Epidemiology, mechanisms of cancerogenesis and prevention of neoplasms. Arkh Patol. 2002;64(2):53-61.

[2] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45.

[3] Bobrovnik SA. Infection, autoimmune diseases, atherosclerosis, infarct, stroke, cancerogenesis: what is in common. Ukr Biokhim Zh. 2002;74(4):135-40.

[4] Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec 19-26;420(6917):860-7.

[5] Keller R, Keist R, Gustafson JE. Antitumor activity of bacteria and bacterial products: enhancement of the tumor-protective effect of bacteria by lipoteichoic acid. Cancer Lett. 1994;82(1):99-104.

[6] Konturek PC, Konturek SJ, Pierzchalski P, Bielanski W, Duda A, Marlicz K, Starzynska T, Hahn EG. Cancerogenesis in Helicobacter pylori infected stomach--role of growth factors, apoptosis and cyclooxygenases. Med Sci Monit. 2001;7(5):1092-107.

[7] Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech. 2003;60(1):64-9.

[8] Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103(3):481-90.

[9] Maeda H, Akaike T, Wu J, Noguchi Y, Sakata Y. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology. 1996;33(1-3):222-30.

[10] Terman DS. Protein A and staphylococcal products in neoplastic disease. Crit Rev Oncol Hematol. 1985;4(2):103-24.

[11] Quan WD Jr, Palackdharry CS. Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV. Dis Mon. 1997;43(11):745-808.

[12] Shimizu M, Matsuzawa A, Takeda Y. A novel method for modification of tumor cells with bacterial superantigen with a heterobifunctional cross-linking agent in immunotherapy of cancer. Mol Biotechnol. 2003;25(1):89-94.

[13] Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, He L, Wang J, Cao X. Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response. J Cancer Res Clin Oncol. 2001;127(12):718-26.

[14] Lycke N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol. 2004;6(1):23-32.

[15] Hara I, Sato N, Miyake H, Muramaki M, Hikosaka S, Kamidono S. Introduction of 65 kDa antigen of Mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy. Microbiol Immunol. 2004;48(4):289-95.

[16] Mastrangelo MJ, Maguire HC Jr, Sato T, Nathan FE, Berd D. Active specific immunization in the treatment of patients with melanoma. Semin Oncol. 1996;23(6):773-81.

[17] Sekine K, Ohta J, Onishi M, Tatsuki T, Shimokawa Y, Toida T, Kawashima T, Hashimoto Y. Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis. Biol Pharm Bull. 1995;18(1):148-53.

[18] Wang JE, Dahle MK, McDonald M, Foster SJ, Aasen AO, Thiemermann C. Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock. 2003;20(5):402-14.

[19] Sriskandan S, Cohen J. Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Infect Dis Clin North Am. 1999;13(2):397-412.

[20] Calvinho LF, Almeida RA, Oliver SP. Influence of bacterial factors on proliferation of bovine mammary epithelial cells. Rev Argent Microbiol. 2001;33(1):28-35.

[21] Heumann D, Glauser MP, Calandra T. Molecular basis of host-pathogen interaction in septic shock. Curr Opin Microbiol. 1998;1(1):49-55.

[22] Bruserud O, Wendelbo O, Paulsen K. Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts. Eur J Haematol. 2004;73(5):340-50.

[23] Okamoto M, Ohe G, Oshikawa T, Furuichi S, Nishikawa H, Tano T, Ahmed SU, Yoshida H, Moriya Y, Saito M, Sato M. Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus. Cancer Immunol Immunother. 2001;50(8):408-16.

[24] Okamoto M, Ohe G, Furuichi S, Nishikawa H, Oshikawa T, Tano T, Ahmed SU, Yoshida H, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M. Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells. Anticancer Res. 2002;22(6A):3229-39.

[25] Gao JJ, Xue Q, Zuvanich EG, Haghi KR, Morrison DC. Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect Immun. 2001;69(2):751-7.

[26] Levels JH, Abraham PR, van Barreveld EP, Meijers JC, van Deventer SJ. Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun. 2003;71(6):3280-4.

[27] Kutsenok VV, Skivka LM, Gorobetc OB, Lozinski MO, Borisevich A. H, Choline VV, Gamaleja NF 5-Aminolevulinic acid as a photosensitizer for photodynamic tumor therapy (preclinical studies). Onkologiia. 2004. 5(3):225–230.

[28] Rashba Ye. YA., Matsyuk V. M., Musiyenko V. I. A-17 homogenizer. Disintegration of microorganisms. Pushchino-na-Oke, 1972:159-162.

[29] Archibald AR Research Methods carbohydrates. M: Vyssh. shkola,, 1975. 350.

[30] Shashkov AS, Streshinskaya GM, Kozlova YuI, Potekhina NV, Taran VV, Evtushenko LI, Naumova IB. Structure of cell wall teichoic acid of Nocardiopsis alborubida. Biokhimiia. 1997; 62(10):1327–31.

[31] Taussky HB, Shorr E., Kurzmann G. A microcolorimetric method for the determination of inorganic phosphorus. J Biol Chem. 1953;202(2):675-85.

[32] Glaser L., Burger M. The synthesis of teichoic acid. 3 Glucosylation of poly glycerolphosphate. J Biol Chem. 1964;239:3187-91.

[33] Streshinskaya GM, Kozlova YuI, Evtushenko LI, Taran VV, Shashkov AS, Naumova IB. Teichoic acid of Nocardiopsis ssp. VKM Ac-1457 cell walls. Biokhimiia. 1996; 61(2):378–82.

[34] Skivka LM, Putnikov AV, Pozur VV, Pozur VK. Effect intaktyvovanoho S. aureus growth Lewis carcinoma in mice. Visn. ONU., 2004. 10, 3:155-162.

[35] Kengatharan KM, De Kimpe SJ, Thiemermann C. Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock. Br J Pharmacol. 1996;119(7):1411-21.

[36] Nau R, Eiffert H. Minimizing the release of proinflammatory and toxic bacterial products within the host: a promising approach to improve outcome in life-threatening infections. FEMS Immunol Med Microbiol. 2005;44(1):1-16.

[37] Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev. 2003;16(4):637-46.

[38] Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002;168(2):554-61.

[39] Netea MG, van der Graaf C, Van der Meer JW, Kullberg BJ. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol. 2004;75(5):749-55.

[40] Moreno C., Sanchez-Ibarrola A. Toll type receptors: molecular bases of the relationship between innate and adaptation responses of the immune system. Rev Med Univ Navarra. 2003;47(3):29-33.

[41] Palaniyar N, Nadesalingam J, Reid KB. Pulmonary innate immune proteins and receptors that interact with gram-positive bacterial ligands. Immunobiology. 2002;205(4-5):575-94.

[42] Middelveld RJ, Alving K. Synergistic septicemic action of the gram-positive bacterial cell wall components peptidoglycan and lipoteichoic acid in the pig in vivo. Shock. 2000;13(4):297-306.